Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 21

1.

Clinical development of new drug-radiotherapy combinations.

Sharma RA, Plummer R, Stock JK, Greenhalgh TA, Ataman O, Kelly S, Clay R, Adams RA, Baird RD, Billingham L, Brown SR, Buckland S, Bulbeck H, Chalmers AJ, Clack G, Cranston AN, Damstrup L, Ferraldeschi R, Forster MD, Golec J, Hagan RM, Hall E, Hanauske AR, Harrington KJ, Haswell T, Hawkins MA, Illidge T, Jones H, Kennedy AS, McDonald F, Melcher T, O'Connor JP, Pollard JR, Saunders MP, Sebag-Montefiore D, Smitt M, Staffurth J, Stratford IJ, Wedge SR; NCRI CTRad Academia-Pharma Joint Working Group.

Nat Rev Clin Oncol. 2016 Oct;13(10):627-42. doi: 10.1038/nrclinonc.2016.79. Epub 2016 Jun 1.

PMID:
27245279
2.

Plasma Metabolomic Changes following PI3K Inhibition as Pharmacodynamic Biomarkers: Preclinical Discovery to Phase I Trial Evaluation.

Ang JE, Pandher R, Ang JC, Asad YJ, Henley AT, Valenti M, Box G, de Haven Brandon A, Baird RD, Friedman L, Derynck M, Vanhaesebroeck B, Eccles SA, Kaye SB, Workman P, de Bono JS, Raynaud FI.

Mol Cancer Ther. 2016 Jun;15(6):1412-24. doi: 10.1158/1535-7163.MCT-15-0815. Epub 2016 Apr 5.

3.

Understanding Oestrogen Receptor Function in Breast Cancer and its Interaction with the Progesterone Receptor. New Preclinical Findings and their Clinical Implications.

Baird RD, Carroll JS.

Clin Oncol (R Coll Radiol). 2016 Jan;28(1):1-3. doi: 10.1016/j.clon.2015.10.005. Epub 2015 Nov 6. No abstract available.

PMID:
26548499
4.

A Bayesian adaptive design for biomarker trials with linked treatments.

Wason JM, Abraham JE, Baird RD, Gournaris I, Vallier AL, Brenton JD, Earl HM, Mander AP.

Br J Cancer. 2015 Sep 1;113(5):699-705. doi: 10.1038/bjc.2015.278. Epub 2015 Aug 11.

5.

Antitumor activity in RAS-driven tumors by blocking AKT and MEK.

Tolcher AW, Khan K, Ong M, Banerji U, Papadimitrakopoulou V, Gandara DR, Patnaik A, Baird RD, Olmos D, Garrett CR, Skolnik JM, Rubin EH, Smith PD, Huang P, Learoyd M, Shannon KA, Morosky A, Tetteh E, Jou YM, Papadopoulos KP, Moreno V, Kaiser B, Yap TA, Yan L, de Bono JS.

Clin Cancer Res. 2015 Feb 15;21(4):739-48. doi: 10.1158/1078-0432.CCR-14-1901. Epub 2014 Dec 16.

6.

The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial.

Sandhu SK, Schelman WR, Wilding G, Moreno V, Baird RD, Miranda S, Hylands L, Riisnaes R, Forster M, Omlin A, Kreischer N, Thway K, Gevensleben H, Sun L, Loughney J, Chatterjee M, Toniatti C, Carpenter CL, Iannone R, Kaye SB, de Bono JS, Wenham RM.

Lancet Oncol. 2013 Aug;14(9):882-92. doi: 10.1016/S1470-2045(13)70240-7. Epub 2013 Jun 28.

PMID:
23810788
7.

Genetic heterogeneity in breast cancer: the road to personalized medicine?

Baird RD, Caldas C.

BMC Med. 2013 Jun 18;11:151. doi: 10.1186/1741-7015-11-151. Review.

8.

The role of surgery in patients with advanced gynaecological cancers participating in phase I clinical trials.

Vitfell-Pedersen J, Yap TA, Moreno V, Baird RD, Khan AZ, Barton DP, Kaye SB.

Eur J Gynaecol Oncol. 2012;33(2):211-3.

PMID:
22611966
9.

First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors.

Yap TA, Yan L, Patnaik A, Fearen I, Olmos D, Papadopoulos K, Baird RD, Delgado L, Taylor A, Lupinacci L, Riisnaes R, Pope LL, Heaton SP, Thomas G, Garrett MD, Sullivan DM, de Bono JS, Tolcher AW.

J Clin Oncol. 2011 Dec 10;29(35):4688-95. doi: 10.1200/JCO.2011.35.5263. Epub 2011 Oct 24.

PMID:
22025163
10.

Baseline circulating tumor cell counts significantly enhance a prognostic score for patients participating in phase I oncology trials.

Olmos D, Baird RD, Yap TA, Massard C, Pope L, Sandhu SK, Attard G, Dukes J, Papadatos-Pastos D, Grainger P, Kaye SB, de Bono JS.

Clin Cancer Res. 2011 Aug 1;17(15):5188-96. doi: 10.1158/1078-0432.CCR-10-3019. Epub 2011 Apr 29.

11.

Weekly paclitaxel in the treatment of recurrent ovarian cancer.

Baird RD, Tan DS, Kaye SB.

Nat Rev Clin Oncol. 2010 Oct;7(10):575-82. doi: 10.1038/nrclinonc.2010.120. Epub 2010 Aug 3. Review.

PMID:
20683437
12.

Phase I safety, pharmacokinetic, and pharmacogenomic trial of ES-285, a novel marine cytotoxic agent, administered to adult patients with advanced solid tumors.

Baird RD, Kitzen J, Clarke PA, Planting A, Reade S, Reid A, Welsh L, López Lázaro L, de las Heras B, Judson IR, Kaye SB, Eskens F, Workman P, deBono JS, Verweij J.

Mol Cancer Ther. 2009 Jun;8(6):1430-7. doi: 10.1158/1535-7163.MCT-08-1167. Epub 2009 Jun 9.

13.

Applications of the amino-Cope rearrangement: synthesis of tetrahydropyran, delta-lactone and piperidine targets.

Allin SM, Essat M, Pita CH, Baird RD, McKee V, Elsegood M, Edgar M, Andrews DM, Shah P, Aspinall I.

Org Biomol Chem. 2005 Mar 7;3(5):809-15. Epub 2005 Jan 26.

PMID:
15731867
14.

Drug resistance reversal--are we getting closer?

Baird RD, Kaye SB.

Eur J Cancer. 2003 Nov;39(17):2450-61. Review.

PMID:
14602131
15.
16.

Carcinoma-induced diffuse pulmonary haemorrhage.

Baird RD, Shee CD.

Hosp Med. 2002 Mar;63(3):176-7. No abstract available.

PMID:
11933824
18.
19.
20.

Relation of Lymphocytic Choriomeningitis to Acute Aseptic Meningitis (Wallgren).

Baird RD, Rivers TM.

Am J Public Health Nations Health. 1938 Jan;28(1):47-53. No abstract available.

Supplemental Content

Loading ...
Support Center